Mice deficient in IFN-β develop predominantly N2-like TANs, whereas melanoma patients treated with type I IFN therapy exhibit a shift toward N1-like neutrophil profiles, underscoring the relevance of these mechanisms in both murine models and human cancer (Figure 1) [26]. The gene discussed is IFNB1; the disease is melanoma.